Publication:
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial

dc.contributor.coauthorDinkelborg, Katja
dc.contributor.coauthorKahlhoefer, Julia
dc.contributor.coauthorDoerge, Petra
dc.contributor.coauthorHardtke, Svenja
dc.contributor.coauthorCaruntu, Florin Alexandru
dc.contributor.coauthorCurescu, Manuela G.
dc.contributor.coauthorYalcin, Kendal
dc.contributor.coauthorAkarca, Ulus S.
dc.contributor.coauthorGurel, Selim
dc.contributor.coauthorZeuzem, Stefan
dc.contributor.coauthorErhardt, Andreas
dc.contributor.coauthorLueth, Stefan
dc.contributor.coauthorPapatheodoridis, George, V
dc.contributor.coauthorKeskin, Onur
dc.contributor.coauthorPort, Kerstin
dc.contributor.coauthorRadu, Monica
dc.contributor.coauthorCelen, Mustafa K.
dc.contributor.coauthorIdilman, Ramazan
dc.contributor.coauthorWeber, Kristina
dc.contributor.coauthorStift, Judith
dc.contributor.coauthorWittkop, Ulrike
dc.contributor.coauthorHeidrich, Benjamin
dc.contributor.coauthorMederacke, Ingmar
dc.contributor.coauthorvon der Leyen, Heiko
dc.contributor.coauthorDienes, Hans Peter
dc.contributor.coauthorCornberg, Markus
dc.contributor.coauthorKoch, Armin
dc.contributor.coauthorManns, Michael P.
dc.contributor.coauthorWedemeyer, Heiner
dc.contributor.coauthorDeterding, Katja
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorYurdaydın, Cihan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:41:20Z
dc.date.issued2023
dc.description.abstractBackground and Aims: Infection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown to be associated with worse patient-reported outcomes. Until recently, only pegylated interferon alfa could be used to treat hepatitis delta. Methods: Here, we investigated quality of life (QOL) as assessed by the Short Form 36 Health Survey (SF-36) in patients undergoing antiviral therapy with pegylated interferon alfa (PEG-IFNa-2a)-based treatment in the HIDIT-II trial. HIDIT-II was a randomized prospective trial exploring PEG-IFNa-2a with tenofovir disoproxil (TDF) or placebo for 96 weeks in patients with compensated hepatitis delta. Surveys completed by 83 study participants before, during, and after treatments were available. Results: Overall, we observed a reduced QOL of HDV patients compared with a reference population, both in physical as well as mental scores. Interestingly, PEG-IFNa-2a treatment showed only minor impairment of the QOL during therapy. Moreover, HDV-RNA clearance was not associated with relevant changes in physical or social SF-36 scores, whereas an improvement of fibrosis during treatment was associated with increased QOL. Overall, slight improvements of the QOL scores were observed 24 weeks after the end of treatment as compared with baseline. TDF co-treatment had no influence on QOL. Conclusions: Overall, our findings suggest that PEG-IFNa-2a was reasonably tolerated even over a period of 96 weeks by hepatitis D patients reporting SF-36 questionnaires. Of note, several patients may benefit from PEG-IFNa-2a-based therapies with off-treatment improvements in quality of life.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue8
dc.description.openaccesshybrid
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume43
dc.identifier.doi10.1111/liv.15602
dc.identifier.eissn1478-3231
dc.identifier.issn1478-3223
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85159194675
dc.identifier.urihttps://doi.org/10.1111/liv.15602
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23587
dc.identifier.wos999103300001
dc.keywordsHepatitis D
dc.keywordsInterferon-based therapy
dc.keywordsQuality of life
dc.keywordsSF36
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofLiver International
dc.subjectGastroenterology
dc.subjectHepatology
dc.titleQuality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorYurdaydın, Cihan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05483.pdf
Size:
2.43 MB
Format:
Adobe Portable Document Format